Related Experiment Videos
Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement
|January 1, 1987
Summary
High-dose interferon alfa-2a shows promise for advanced cutaneous T-cell lymphomas, offering significant responses in 45% of patients refractory to standard treatments. Further research in earlier stages and combination therapies is recommended.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, are indolent lymphomas with early systemic spread.
- Current systemic chemotherapy offers limited cure rates for CTCL, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose recombinant interferon alfa-2a in patients with advanced, therapy-refractory cutaneous T-cell lymphomas.
Main Methods:
- A study involving 20 patients with advanced CTCL (stages II-IV) who had failed at least two prior therapies.
- Treatment administered was high-dose recombinant interferon alfa-2a.
- Response assessment included objective partial or complete responses within 3 months and maximal response over one year.
Main Results:
- Nine out of 20 patients (45%) achieved objective partial or complete responses within 3 months.
- Maximal responses were observed up to one year, with a median response duration of 5.5 months.
- Complete responses persisted for over 2 years; responses were consistent across cutaneous and extracutaneous sites and prior treatment history.
- Toxicity included a flu-like syndrome requiring dose reduction in all patients, with some experiencing transient liver, renal, and granulocyte count changes.
Conclusions:
- Interferon alfa-2a demonstrates significant activity against advanced cutaneous T-cell lymphomas.
- Further investigation in earlier stages of CTCL and in combination with other agents is warranted.